[HTML][HTML] A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose …
Background Pneumococcal disease (PD) remains a major health concern with considerable
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol, J Jones… - Vaccine, 2023 - europepmc.org
Background Pneumococcal disease (PD) remains a major health concern with considerable
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Pneumococcal disease (PD) remains a major health concern with considerable
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol, J Jones… - Vaccine, 2023 - avesis.ankara.edu.tr
© 2022Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
V114-029 PNEU-PED study group - Vaccine, 2023 - mahidol.elsevierpure.com
Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol, J Jones… - Vaccine, 2023 - cris.bgu.ac.il
Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol, J Jones… - 2023 - cabidigitallibrary.org
Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
V114-029 PNEU-PED study group - Vaccine, 2023 - researchexperts.utmb.edu
Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of …
R Lupinacci, R Rupp, O Wittawatmongkol, J Jones… - Vaccine, 2023 - avesis.ankara.edu.tr
© 2022Background: Pneumococcal disease (PD) remains a major health concern with
considerable morbidity and mortality in children. Currently licensed pneumococcal …
considerable morbidity and mortality in children. Currently licensed pneumococcal …